Imbalance of Circulating Follicular Regulatory and Follicular Helper T Cell Subpopulations Is Associated with Disease Progression and Serum CYFRA 21-1 Levels in Patients with Non-small Cell Lung Cancer

Abstract

Objective

This study aimed to investigate the changes of follicular helper T (TFH) and follicular regulatory T (TFR) cell subpopulations in patients with non-small cell lung cancer (NSCLC) and their significance.

Methods

Peripheral blood was collected from 58 NSCLC patients at different stages and 38 healthy controls. Flow cytometry was used to detect TFH cell subpopulation based on programmed death 1 (PD-1) and inducible co-stimulator (ICOS), and TFR cell subpopulation based on cluster determinant 45RA (CD45RA) and forkhead box protein P3 (FoxP3). The levels of interleukin-10 (IL-10), interleukin-17a (IL-17a), interleukin-21 (IL-21), and transforming growth factor-β (TGF-β) in the plasma were measured, and changes in circulating B cell subsets and plasma IgG levels were also analyzed. The correlation between serum cytokeratin fragment antigen 21-1 (CYFRA 21-1) levels and TFH, TFR, or B cell subpopulations was further explored.

Results

The TFR/TFH ratio increased significantly in NSCLC patients. The CD45RA ⁺FoxP3 ^int TFR subsets were increased, with their proportions increasing in stages II to III and decreasing in stage IV. PD-1 ⁺ICOS ⁺TFH cells showed a downward trend with increasing stages. Plasma IL-21 and TGF-β concentrations were increased in NSCLC patients compared with healthy controls. Plasmablasts, plasma IgG levels, and CD45RA ⁺FoxP3 ^int TFR cells showed similar trends. TFH numbers and plasmablasts were positively correlated with CYFRA 21-1 in stages I–III and negatively correlated with CYFRA 21-1 in stage IV.

Conclusion

Circulating TFH and TFR cell subpopulations and plasmablasts dynamically change in different stages of NSCLC, which is associated with serum CYFRA 21-1 levels and reflects disease progression.

Keywords

non-small cell lung cancer / follicular helper T cells / follicular regulatory T cells / progression

References

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115–132
[2]	Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol, 2012,30:429–457
[3]	Shi W, Li X, Cha Z, et al. Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer. DNA Cell Biol, 2014,33(6):355–360
[4]	Zhao Y, Zhao M, Li M, et al. Alterations in Helios+ T Cell Subsets in Peripheral Blood of Early-Stage Lung Adenocarcinoma Patients: Implications for Early Diagnosis. Immunobiology, 2023,228(6):152749
[5]	Guo Z, Liang H, Xu Y, et al. The Role of Circulating T Follicular Helper Cells and Regulatory Cells in Non-Small Cell Lung Cancer Patients. Scand J Immunol, 2017,86(2):107–112
[6]	Ma QY, Huang DY, Zhang HJ, et al. Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer. Int Immunopharmacol, 2016,41:1–7
[7]	Liu C, Wang D, Lu S, et al. Increased circulating follicular Treg cells are associated with lower levels of autoantibodies in patients with rheumatoid arthritis in stable remission. Arthritis Rheumatol, 2018,70(5):711–721
[8]	Linterman MA, Vinuesa CG. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol, 2010,32(2):183–196
[9]	Laurent C, Fazilleau N, Brousset P. A novel subset of T-helper cells: follicular T-helper cells and their markers. Haematologica, 2010,95(3):356–358
[10]	Kim JW, Lee J, Hong SM, et al. Circulating CCR7loPD-1hi follicular helper T cells indicate disease activity and glandular inflammation in patients with primary Sj?gren’s syndrome. Immune Netw, 2019,19(4):e26
[11]	Fan X, Jin T, Zhao S, et al. Circulating CCR7+ ICOS+ memory T follicular helper cells in patients with multiple sclerosis. PLoS One, 2015,10(7):e0134523
[12]	Wang L, Sun X, Qiu J, et al. Increased numbers of circulating ICOS+ follicular helper T and CD38+ plasma cells in patients with newly diagnosed primary biliary cirrhosis. Dig Dis Sci, 2015,60(2):405–413
[13]	Garcia-Valdecasas Gayo S, Ruiz-Alvarez MJ, Gonzalez-Gay D, et al. CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value. Adv Lab Med, 2020,1(4):20200005
[14]	Han Z, Tian M, Shi F, et al. Clinical significance of serum tumor markers in patients with lung cancer. Zhongguo Jiceng Yiyao (Chinese), 2011,2621-2623
[15]	Wankhede D. Evaluation of Eighth AJCC TNM sage for lung cancer NSCLC: a meta-analysis. Ann Surg Oncol, 2021,28(1):142–147
[16]	Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, et al. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Clin Lab, 2011,57(11–12):1011–1014
[17]	Ueno H. T follicular helper cells in human autoimmunity. Curr Opin Immunol, 2016,43:24–31
[18]	Sefer AP, Charbonnier LM, Kasap N, et al. A patient with novel ICOS mutation presented with progressive loss of B cells. J Clin Immunol, 2021,41(1):251–255
[19]	Czarnowicki T, Gonzalez J, Bonifacio KM, et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol, 2016,137(1):118–129.e5
[20]	Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer, 2015,15(6):361–370
[21]	Hristodorov D, Fischer R, Linden L. With or without sugar?(A) glycosylation of therapeutic antibodies. Mol Biotechnol, 2013,54(3):1056–1068
[22]	Tan TT, Coussens LM. Coussens, Humoral immunity, inflammation and cancer. Curr Opin Immunol, 2007,19(2):209–216
[23]	Long D, Chen Y, Wu H, et al. Clinical significance and immunobiology of IL-21 in autoimmunity. J Autoimmun, 2019,99:1–14
[24]	Li L, Ma Y, Xu Y. Follicular regulatory T cells infiltrated the ovarian carcinoma and resulted in CD8 T cell dysfunction dependent on IL-10 pathway. Int Immunopharmacol, 2019,68:81–87
[25]	Zhang W, Borcherding N, Kolb R. IL-1 signaling in tumor microenvironment. Adv Exp Med Biol, 2020,1240:1–23
[26]	Baker KJ, Brint E, Houston A. Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/IL-23 axis. Br J Cancer, 2023,128(5):735–747
[27]	Molina R, Jo J, Zanón G, et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer, 1996,74(7):1126–1131
[28]	Muley T, Fetz TH, Dienemann H, et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer, 2008,60(3):408–415